Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | IP6K1 | Q92551 | 11/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.35 |
| ▸ | LIPE | Q05469 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1108857 | 0.93 | HSD11B1 (0.46) | HSD11B1CYP2C9IP6K1 | |
| SCHEMBL1108906 | 0.91 | HSD11B1 (0.43) | HSD11B1CYP2C9IP6K1 | |
| SCHEMBL1108855 | 0.90 | HSD11B1 (0.42) | HSD11B1IP6K1FPR2PROKR1 | |
| SCHEMBL13436648 | 0.90 | HSD11B1 (0.39) | HSD11B1IP6K1 | |
| SCHEMBL1108905 | 0.86 | HSD11B1 (0.42) | HSD11B1IP6K1 | |
| SCHEMBL1108912 | 0.84 | HSD11B1 (0.41) | HSD11B1IP6K1 | |
| SCHEMBL1108862 | 0.80 | CYP2C19 (0.43) | HSD11B1LMNACYP2C9SMN1; SMN2LIPE | |
| SCHEMBL1108902 | 0.80 | IP6K1 (0.38) | HSD11B1IP6K1 | |
| SCHEMBL1108897 | 0.79 | IP6K1 (0.39) | IP6K1 | |
| SCHEMBL1108896 | 0.79 | IP6K1 (0.37) | IP6K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153631-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153631-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-7683059-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683059-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20100062972-A1 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | AMGEN INC. | 2010-03-11 | — | — | US | disclosed |
| US-20100062972-A1 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | AMGEN INC. | 2010-03-11 | — | — | US | disclosed |
| US-20080249084-A1 | Triazole Compounds and Uses Related Thereto | AMGEN SF LLC | 2008-10-09 | — | — | US | disclosed |
| US-20080249084-A1 | Triazole Compounds and Uses Related Thereto | AMGEN SF LLC | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100062972-A1 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | HSD11B1, HSD17B1, HSD17B3 | HSD11B1 1/4885LMNA 4295/4885CYP2C9 118/4885 |
| US-20080249084-A1 | Triazole Compounds and Uses Related Thereto | GPR119, CYP11B2, CYP11B1 | HSD11B1 41/4885LMNA 4194/4885CYP2C9 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.